Patents by Inventor Roberto Latini

Roberto Latini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210156875
    Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of DKK3 in a sample from the subject, and comparing the amount of DKK3 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure.
    Type: Application
    Filed: January 29, 2021
    Publication date: May 27, 2021
    Applicants: Roche Diagnostics Operations, Inc., Universitaet Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Johann Karl, Peter Kastner, Roberto Latini, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen, Andre Ziegler, Manuel Dietrich, Jennifer Meessen, Ulrich Schotten
  • Publication number: 20200371114
    Abstract: The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.
    Type: Application
    Filed: December 19, 2019
    Publication date: November 26, 2020
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Roberto Latini, Serge Masson, Dirk Block, Christian Zaugg, Thomas Dieterle, Edelgard Kaiser, Johann Karl, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen
  • Patent number: 10557858
    Abstract: Described is a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from B-type natriuretic peptide (BNP) or N-terminal pro B-type natriuretic peptide (NT-proBNP), IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject along with the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: February 11, 2020
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Roberto Latini, Serge Masson, Dirk Block, Christian Zaugg, Thomas Dieterle, Edelgard Kaiser, Johann Karl, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen
  • Publication number: 20190353666
    Abstract: The present disclosure relates to a method for predicting the risk of recurrence of Atrial Fibrillation in a subject based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. The present disclosure also contemplates a method of diagnosing Atrial Fibrillation in a subject suspected to suffer from Atrial Fibrillation based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. Further envisaged are devices adapted to carry out the method of the present disclosure.
    Type: Application
    Filed: December 12, 2018
    Publication date: November 21, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Herbert Andres, Dirk Block, Johann Karl, Peter Kastner, Ursula-Henrike Wienhues-Thelen, Roberto Latini, Serge Masson, Andre Ziegler, Edelgard Kaiser, Stefan Palme, Markus Thomas, Simona Barlera
  • Publication number: 20190162737
    Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of ESM-1 in a sample from the subject, and comparing the amount of ESM-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure.
    Type: Application
    Filed: February 1, 2019
    Publication date: May 30, 2019
    Applicants: Roche Diagnostics Operations, Inc., Maastricht University Medical Center
    Inventors: Johann Karl, Peter Kastner, Roberto Latini, Serge Masson, Ursula-Henrike Wienhues-Thelen, Andre Ziegler, Manuel Dietrich, Ulrich Schotten, Vinzent Rolny
  • Publication number: 20180196067
    Abstract: The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.
    Type: Application
    Filed: March 5, 2018
    Publication date: July 12, 2018
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Dirk Block, Roberto Latini, Serge Masson, Ursula-Henrike Wienhues-Thelen, Christian Zaugg
  • Publication number: 20170227552
    Abstract: The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.
    Type: Application
    Filed: April 28, 2017
    Publication date: August 10, 2017
    Inventors: Roberto Latini, Serge Masson, Dirk Block, Christian Zaugg, Thomas Dieterle, Edelgard Kaiser, Johann Karl, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen
  • Publication number: 20170074892
    Abstract: The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.
    Type: Application
    Filed: November 23, 2016
    Publication date: March 16, 2017
    Inventors: Dirk Block, Roberto Latini, Serge Masson, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Andre Ziegler
  • Publication number: 20150233946
    Abstract: The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.
    Type: Application
    Filed: May 6, 2015
    Publication date: August 20, 2015
    Inventors: Dirk Block, Roberto Latini, Serge Masson, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Andre Ziegler
  • Publication number: 20150185230
    Abstract: The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.
    Type: Application
    Filed: March 11, 2015
    Publication date: July 2, 2015
    Inventors: Dirk Block, Roberto Latini, Serge Masson, Ursula-Henrike Wienhues-Thelen, Christian Zaugg
  • Patent number: 7550269
    Abstract: A method for the early determination of the risk of death or heart failure in infarction patients, and the risk of death, relapse or complications in ictus patients, the method being based on the determination of PTX3 from plasma or blood.
    Type: Grant
    Filed: August 24, 2006
    Date of Patent: June 23, 2009
    Inventors: Roberto Latini, Giuseppi Peri, Alberto Mantovani, Aldo P. Maggioni
  • Publication number: 20060286617
    Abstract: A method for the early determination of the risk of death or heart failure in infarction patients, and the risk of death, relapse or complications in ictus patients, the method being based on the determination of PTX3 from plasma or blood.
    Type: Application
    Filed: August 24, 2006
    Publication date: December 21, 2006
    Inventors: Roberto Latini, Giuseppi Peri, Alberto Mantovani, Aldo Maggioni
  • Publication number: 20040137544
    Abstract: A method for the early determination of the risk of death or heart failure in infarction patients, and the risk of death, relapse or complications in ictus patients, the method being based on the determination of PTX3 from plasma or blood.
    Type: Application
    Filed: October 31, 2003
    Publication date: July 15, 2004
    Inventors: Roberto Latini, Giuseppi Peri, Alberto Mantovani, Aldo P. Maggioni